ArticleNeuro-oncology2025

Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.

Lauren R Schaff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.